Publicaciones en colaboración con investigadores/as de Hospital Universitario Central de Asturias (41)

2023

  1. Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort

    International Journal of Infectious Diseases, Vol. 137, pp. 134-143

2022

  1. Economic evaluations of radioembolization with Itrium-90 microspheres in hepatocellular carcinoma: a systematic review

    BMC Gastroenterology, Vol. 22, Núm. 1

  2. Outpatient Parenteral Antibiotic Treatment vs Hospitalization for Infective Endocarditis: Validation of the OPAT-GAMES Criteria

    Open Forum Infectious Diseases, Vol. 9, Núm. 9

2021

  1. Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study

    European Journal of Clinical Nutrition, Vol. 75, Núm. 9, pp. 1368-1382

2019

  1. Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 3, pp. 355-364

  2. Very low disease activity, DAPSA remission, and impact of disease in a Spanish population with psoriatic arthritis

    Journal of Rheumatology, Vol. 46, Núm. 7, pp. 710-715

2018

  1. Patient-reported outcomes in european spondyloarthritis patients: A systematic review of the literature

    Patient Preference and Adherence, Vol. 12, pp. 733-747

  2. Recommendations of the Spanish Society of Rheumatology on treatment and use of systemic biological and non-biological therapies in psoriatic arthritis

    Reumatologia Clinica, Vol. 14, Núm. 5, pp. 254-268

2017

  1. Identification and management of comorbidity in psoriatic arthritis: evidence- and expert-based recommendations from a multidisciplinary panel from Spain

    Rheumatology International, Vol. 37, Núm. 8, pp. 1239-1248

2016

  1. Urine metabolome profiling of immune-mediated inflammatory diseases

    BMC Medicine, Vol. 14, Núm. 1

2015

  1. A deletion at adamts9-magi1 locus is associated with psoriatic arthritis risk

    Annals of the Rheumatic Diseases, Vol. 74, Núm. 10, pp. 1875-1881

2014

  1. PDE3A-SLCO1C1 locus is associated with response to anti-tumor necrosis factor therapy in psoriatic arthritis

    Pharmacogenomics, Vol. 15, Núm. 14, pp. 1763-1769

  2. Standards of care for patients with spondyloarthritis

    Rheumatology International, Vol. 34, Núm. 2, pp. 165-170

2013

  1. Comparación de 2 estrategias de derivación en el diagnóstico de la espondiloartritis axial en España. Estudio RADAR

    Reumatologia Clinica, Vol. 9, Núm. 6, pp. 348-352

  2. Diferente expresión clínica de los pacientes con espondilitis anquilosante según el sexo en función del tiempo de evolución. Datos de REGISPONSER

    Reumatologia Clinica, Vol. 9, Núm. 4, pp. 221-225

2012

  1. Risk variants for psoriasis vulgaris in a large case-control collection and association with clinical subphenotypes

    Human Molecular Genetics, Vol. 21, Núm. 20, pp. 4549-4557

2011

  1. Documento SER de consenso sobre el uso de terapias biológicas en la artritis psoriásica

    Reumatologia Clinica, Vol. 7, Núm. 3, pp. 179-188

  2. Fine mapping of a major histocompatibility complex in ankylosing spondylitis: Association of the HLA-DPA1 and HLA-DPB1 regions

    Arthritis and Rheumatism, Vol. 63, Núm. 11, pp. 3305-3312

  3. High-dose etanercept in ankylosing spondylitis: Results of a 12-week randomized, double blind, controlled multicentre study (LOADET study)

    Rheumatology, Vol. 50, Núm. 10, pp. 1828-1837

2008

  1. Multiple lentigines confined to resolving psoriatic plaques in a patient treated with adalimumab

    Dermatology